Newsletter

028300 - HLB Co., Ltd.

028300 Summary

Biopharma

Stock Price & Overview

₩32,950 -800 (-2.37%) Close · Sep 7, 2026 KST

KOSDAQ | ₩KRW | Close: ₩32,950 ≈ US$24 · Market cap ₩4.4tn (≈ $3.1bn)

Home › 028300 › Filings

5% Ownership Report — Short Form

DART

HLB Co., Ltd.

Filed Sep 7, 2026 KST · Ownership · receipt 20260907000092

kstock has not written this one up. The title above is a translation of the Korean form name; the filing itself is on DART, in Korean.

Read the original on DART ↗ Korean. DART is Korea's electronic disclosure system, run by the Financial Supervisory Service — the filing equivalent of EDGAR.

Korean form name: 주식등의대량보유상황보고서(약식)

028300

Price: ₩32,950
Change: -2.37%
Market cap: ₩4.4tn
Prev. close: ₩33,750

028300 Summary Compare to Peers

028300 data on kstock

Financials: 11 fiscal years
Valuation: Daily P/E, P/S, P/B, P/CF
Earnings: Eight quarters
Dividends: Per-share history

Every figure is taken from HLB Co., Ltd.'s own DART filings and matched on IFRS account codes, so a line holds across years where the Korean wording changed.

kstock analysis on 028300

HLB: Rivoceranib Optionality Cannot Hide A ₩121.3bn Half-Year Loss

Sep 4, 1:46 PM

All 028300 analysis

More 028300 filings

028300 - HLB Co., Ltd.

5% Ownership Report — Short Form

028300

028300 data on kstock

kstock analysis on 028300

HLB: Rivoceranib Optionality Cannot Hide A ₩121.3bn Half-Year Loss

More 028300 filings

Adjustment of the conversion price

5% Ownership Report — Large Holdings

Insider / Major Shareholder Holdings Report

Securities issuance result (voluntary)

Loss Incurred on Derivatives Trading

Half-Year Report